Search Results - "Brevard, Julie"

The histamine skin prick test by Brevard, Julie, MPH, Elder, Mary Anne, RN, MS, FNP-C, Berman, Gary, MD, CPI, Tan, Ye, PhD, Volfson, Dmitri, PhD, Ogden, Adam, PhD, Evans, Barbara, RN, MSc, Bednar, Martin M., MD, PhD

Get full text

Two-Minute Skin Anesthesia Through Ultrasound Pretreatment and Iontophoretic Delivery of a Topical Anesthetic: A Feasibility Study by Spierings, Egilius L. H., Brevard, Julie A., Katz, Nathaniel P.

“…ABSTRACT Background and Objectives.  The pain associated with percutaneous procedures is a significant source of distress in clinical practice, especially in…”
Get full text

Connecting to Young Adults: An Online Social Network Survey of Beliefs and Attitudes Associated With Prescription Opioid Misuse Among College Students by Lord, Sarah, Brevard, Julie, Budman, Simon

“…A survey of motives and attitudes associated with patterns of nonmedical prescription opioid medication use among college students was conducted on Facebook, a…”
Get full text

4: Improving young adolescents’ puberty knowledge: A randomized controlled trial by Cousineau, Tara M., Ph.D, Franko, Debra L., Ph.D, Watt, Meredith, M.S.W, Brevard, Julie A., M.P.H, Pappas, Jessica, B.A

Get full text

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials by Beysen, Carine, Schroeder, Patricia, Wu, Eric, Brevard, Julie, Ribadeneira, Maria, Lu, Wei, Dole, Kiran, O'Reilly, Terry, Morrow, Linda, Hompesch, Marcus, Hellerstein, Marc K., Li, Kelvin, Johansson, Lars, Kelly, Patrick F.

“…Aims To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a)…”
Get full text

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial by de la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Levacic, Danijela, Walbert, Tobias, Gan, Hui K, Vieito, Maria, Milhem, Mohammed M, Lipford, Kathryn, Forsyth, Sanjeev, Guichard, Sylvie M, Mikhailov, Yelena, Sedkov, Alexander, Brevard, Julie, Kelly, Patrick F, Mohamed, Hesham, Monga, Varun

“…Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of…”
Get full text

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease by Lal, Ashutosh, Brown, R. Clark Clark, Coates, Thomas D., Kalfa, Theodosia A., Kwiatkowski, Janet L., Brevard, Julie, Potter, Von, Wood, Ken W., Sheth, Sujit

“…Background Sickle cell disease (SCD) and thalassemia are inherited hemoglobinopathies characterized by lifelong anemia. In SCD, a single mutation in the…”
Get full text

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis by Balak, Deepak M.W, van Doorn, Martijn B.A, Arbeit, Robert D, Rijneveld, Rianne, Klaassen, Erica, Sullivan, Tim, Brevard, Julie, Bing Thio, H, Prens, Errol P, Burggraaf, J. (Koos), Rissmann, Robert

“…Abstract Background Aberrant toll-like receptors (TLRs) 7, 8, and 9 activation by self-nucleic acids is implicated in immune-mediated inflammatory diseases…”
Get full text

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) by Wood, Kenneth W., Geib, James, Wu, Eric, Berlin, Jason, Webster, Irena, Ataga, Kenneth I., Howard, Jo, Estepp, Jeremie H., Telen, Marilyn J., Brevard, Julie

“…The hallmark of sickle cell disease (SCD) is hemoglobin S (HbS) polymerization upon deoxygenation, resulting in red blood cell (RBC) sickling, oxidative…”
Get full text

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial by Watts, Justin M, Baer, Maria R, Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J, Dinner, Shira N, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S, Seiter, Karen P, Wei, Andrew H, De Botton, Stephane, Arnan, Montserrat, Donnellan, Will, Schwarer, Anthony P, Récher, Christian, Jonas, Brian A, Ferrell, P Brent, Marzac, Christophe, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie M, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, Cortes, Jorge E

“…Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase…”
Get full text

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial by Cortes, Jorge E., Fenaux, Pierre, Yee, Karen, Recher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C, Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Peterlin, Pierre, Polyanskaya, Olga, Sweeney, Jennifer, Brevard, Julie, Barrett, Emma, De Botton, Stephane

Get full text

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia by Cortes, Jorge E., Esteve, Jordi, Bajel, Ashish, Yee, Karen, Braun, Thorsten, De Botton, Stephane, Peterlin, Pierre, Recher, Christian, Thomas, Xavier, Watts, Justin, Arnan Sangerman, Montserrat, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Lanza, Francesco, Legrand, Olivier, Montesinos, Pau, Patel, Prapti, Prebet, Thomas, Wang, Eunice S., Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Fenaux, Pierre, Wei, Andrew H.

“…Background: Olutasidenib, a potent, selective, oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), has been previously shown, as a…”
Get full text

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML by de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C., Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra K., Jurcic, Joseph G., Krauter, Jürgen, Thomas, Xavier, Watts, Justin M., Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, Cortes, Jorge

“…•Olutasidenib induced durable remissions in patients with mIDH1 R/R AML; transfusion independence was achieved across all response groups.•The side effect…”
Get full text

D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects by Young, Damon, Popiolek, Michael, Trapa, Patrick, Fonseca, Kari R, Brevard, Julie, Gray, David L, Kozak, Rouba

“…Parkinson’s disease is a progressive neurodegenerative disease characterized by striatal dopaminergic loss. L-DOPA treatment replaces lost dopamine and enables…”
Get full text

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies by Patel, Manish R., Garcia-Manero, Guillermo, Paquette, Ronald, Dinner, Shira, Donnellan, William B., Grunwald, Michael R., Ribadeneira, Maria D, Schroeder, Patricia, Brevard, Julie, Wilson, Lindsey, Sweeney, Jennifer, Kelly, Patrick, Lancet, Jeffrey E.

“…▪ Background: BET inhibitors have demonstrated therapeutic potential in hematologic malignancies; however low therapeutic margins have limited clinical…”
Get full text

MyStudentBody-Stress: An Online Stress Management Intervention for College Students by Chiauzzi, Emil, Brevard, Julie, Thurn, Christina, Decembrele, Stacey, Lord, Sarah

“…College students who have high stress levels tend to experience an increased risk of academic difficulties, substance abuse, and emotional problems. To enhance…”
Get full text

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine by Cortes, Jorge E., Wang, Eunice S., Watts, Justin M., Lee, Sangmin, Baer, Maria R., Dao, Kim-Hien, Dinner, Shira, Yang, Jay, Donnellan, William B., Schwarer, Anthony P, Recher, Christian, Kelly, Patrick, Sweeney, Jennifer, Brevard, Julie, Henrick, Patrick, Forsyth, Sanjeev, Guichard, Sylvie, Mohamed, Hesham, Wei, Andrew H.

“…Background: Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematopoietic stem cell disorders with risk of progression to AML. Isocitrate…”
Get full text

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study by Watts, Justin M., Baer, Maria R., Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J., Dinner, Shira, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S., Seiter, Karen, Wei, Andrew H., De Botton, Stephane, Arnan Sangerman, Montserrat, Donnellan, William B., Jonas, Brian A, Ferrell, Paul Brent, Dao, Kim-Hien, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, Cortes, Jorge E.

“…▪ Background: Isocitrate dehydrogenase 1 mutations (IDH1m) occur in 7-14% of AML patients (pts) and approximately 3-4% of MDS pts. Olutasidenib is a highly…”
Get full text

ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY by De la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Fonkem, Ekokobe, Walbert, Tobias, Milhem, Mohammed, Lipford, Kate, Forsyth, Sanjeev, Guichard, Sylvie, Brevard, Julie, Mikhailov, Yelena, Thomson, Blythe, Monga, Varun

“…Abstract BACKGROUND Isocitrate dehydrogenase mutations (mIDH1) are present in > 70% of patients with Grade II/III gliomas resulting in production and…”
Get full text

The histamine skin prick test: An analysis of the method for use in clinical trials by Brevard, Julie, Elder, Mary Anne, Berman, Gary, Tan, Ye, Volfson, Dmitri, Ogden, Adam, Evans, Barbara, Bednar, Martin M

Get full text